Existing investor Novo Ventures contributed to a series C round announced alongside Unchained Labs' acquisition of protein measurement device maker Trinean.
US-based life sciences tool supplier Unchained Labs has raised $13m in a series C round featuring returning Novo Ventures, the corporate venturing arm of pharmaceutical company Novo.
Venture firm Canaan Partners and TPG Biotech, a specialist branch of private equity group TPG, joined Novo Ventures in the round, which took the company’s overall funding to $63m.
Unchained Labs produces tools for biologics research, including biologics stability systems, a protein sizing product and workflow automation systems.
Novo Ventures led Unchained Labs’…
